Skip to content
DataLookout
Menu

NCT07941622

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

StatusNot Yet Recruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Timeframe: Day181

Secondary (11)

Baseline, pre-vaccination sample
1 month after the last dose of primary series:
Before the booster dose:
1 month after the booster dose:
Presence of immediate unsolicited adverse events (AEs)
Show 6 moreShow less
Presence of solicited injection site reactions
Presence of solicited systemic reactions
Presence of unsolicited AEs
Presence of serious adverse events (SAEs)
Presence of related SAEs and fatal case regardless of causality
Presence of AEs leading to study discontinuation

Arms and interventions

Group 1 (the investigational group)Experimental

Hexaxim at 2, 4 and 6 MoA

Group 2 (the comparator group)Active comparator

Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

Biologicals: DTaP-IPV-HB-PRP~T combined vaccine, DTaP-IPV//PRP~T combined vaccine, monovalent Hep B vaccine